 Jeffrey Bennett
Concepts (494)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 76 | 2023 | 115 | 15.660 |
Why?
| | Aquaporin 4 | 53 | 2023 | 87 | 7.480 |
Why?
| | Multiple Sclerosis | 32 | 2023 | 376 | 6.290 |
Why?
| | Immunoglobulin G | 51 | 2023 | 770 | 4.670 |
Why?
| | Autoantibodies | 47 | 2024 | 1345 | 4.640 |
Why?
| | Optic Neuritis | 15 | 2023 | 37 | 4.390 |
Why?
| | B-Lymphocytes | 15 | 2023 | 766 | 1.840 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 16 | 2024 | 44 | 1.800 |
Why?
| | Optic Nerve | 12 | 2023 | 65 | 1.730 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 31 | 1.640 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 25 | 1.460 |
Why?
| | Astrocytes | 13 | 2022 | 162 | 1.340 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 130 | 1.130 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1262 | 1.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 15 | 2023 | 663 | 1.120 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 75 | 1.070 |
Why?
| | Neuroglia | 4 | 2018 | 150 | 1.050 |
Why?
| | Retinal Degeneration | 2 | 2023 | 30 | 0.910 |
Why?
| | Complement System Proteins | 7 | 2019 | 283 | 0.890 |
Why?
| | Epitopes | 7 | 2023 | 435 | 0.890 |
Why?
| | Humans | 130 | 2024 | 114624 | 0.880 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 51 | 0.870 |
Why?
| | Natalizumab | 4 | 2020 | 46 | 0.860 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 646 | 0.850 |
Why?
| | Methylprednisolone | 1 | 2023 | 81 | 0.840 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 30 | 0.810 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 106 | 0.800 |
Why?
| | Autoimmunity | 4 | 2017 | 813 | 0.780 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 72 | 0.770 |
Why?
| | Animals | 55 | 2023 | 31695 | 0.760 |
Why?
| | Immunotherapy | 4 | 2020 | 474 | 0.750 |
Why?
| | Brain | 8 | 2019 | 2371 | 0.720 |
Why?
| | Disease Models, Animal | 15 | 2023 | 3531 | 0.720 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 29 | 0.720 |
Why?
| | Cerebellum | 3 | 2018 | 200 | 0.700 |
Why?
| | Complement Activation | 4 | 2022 | 340 | 0.670 |
Why?
| | Inflammation | 11 | 2023 | 2478 | 0.660 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 18 | 0.650 |
Why?
| | Plasma Cells | 7 | 2017 | 56 | 0.650 |
Why?
| | Complement C1q | 1 | 2019 | 36 | 0.650 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 22 | 0.640 |
Why?
| | Remyelination | 1 | 2018 | 8 | 0.630 |
Why?
| | Central Nervous System | 5 | 2023 | 235 | 0.620 |
Why?
| | Cell Membrane | 3 | 2017 | 680 | 0.620 |
Why?
| | Magnetic Resonance Imaging | 11 | 2023 | 3039 | 0.620 |
Why?
| | Aminopyridines | 1 | 2019 | 81 | 0.620 |
Why?
| | Papilledema | 4 | 2023 | 40 | 0.620 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 69 | 0.610 |
Why?
| | Microglia | 2 | 2019 | 202 | 0.600 |
Why?
| | Pyrroles | 1 | 2019 | 181 | 0.600 |
Why?
| | Organic Chemicals | 1 | 2019 | 112 | 0.590 |
Why?
| | Immunologic Factors | 4 | 2022 | 220 | 0.590 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 378 | 0.580 |
Why?
| | Glucocorticoids | 2 | 2019 | 532 | 0.580 |
Why?
| | Mice | 30 | 2023 | 14860 | 0.580 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 53 | 0.570 |
Why?
| | Disease Management | 2 | 2018 | 560 | 0.570 |
Why?
| | CHO Cells | 8 | 2019 | 138 | 0.560 |
Why?
| | Antigens, CD19 | 5 | 2022 | 91 | 0.560 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.550 |
Why?
| | Spinal Cord | 8 | 2023 | 347 | 0.550 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 113 | 0.550 |
Why?
| | Retina | 5 | 2023 | 263 | 0.550 |
Why?
| | Myelin Sheath | 6 | 2023 | 144 | 0.540 |
Why?
| | Cricetulus | 7 | 2019 | 97 | 0.540 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1230 | 0.540 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 36 | 0.540 |
Why?
| | Mutagenesis | 2 | 2019 | 168 | 0.500 |
Why?
| | Stents | 2 | 2016 | 475 | 0.490 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 83 | 0.480 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 125 | 0.470 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 48 | 0.460 |
Why?
| | Optic Atrophy | 2 | 2011 | 10 | 0.450 |
Why?
| | Temporal Arteries | 4 | 2015 | 47 | 0.450 |
Why?
| | Visual Acuity | 6 | 2021 | 274 | 0.420 |
Why?
| | Adult | 33 | 2023 | 30528 | 0.420 |
Why?
| | Flow Cytometry | 9 | 2023 | 1083 | 0.420 |
Why?
| | Peptide Fragments | 4 | 2023 | 665 | 0.420 |
Why?
| | Antigens, Viral | 3 | 2015 | 176 | 0.410 |
Why?
| | Glial Fibrillary Acidic Protein | 4 | 2023 | 79 | 0.410 |
Why?
| | Axons | 2 | 2022 | 177 | 0.400 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 92 | 0.400 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 45 | 0.400 |
Why?
| | Recurrence | 7 | 2023 | 935 | 0.390 |
Why?
| | Hemodynamics | 1 | 2016 | 1012 | 0.390 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.390 |
Why?
| | Biomarkers | 8 | 2023 | 3408 | 0.380 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 36 | 0.380 |
Why?
| | Cricetinae | 6 | 2019 | 253 | 0.380 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 72 | 0.370 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 140 | 0.370 |
Why?
| | Gene Targeting | 1 | 2011 | 75 | 0.370 |
Why?
| | Nerve Degeneration | 1 | 2010 | 40 | 0.360 |
Why?
| | Eye Diseases | 2 | 2020 | 76 | 0.360 |
Why?
| | Stilbenes | 1 | 2010 | 36 | 0.360 |
Why?
| | Mice, Inbred C57BL | 10 | 2023 | 4689 | 0.360 |
Why?
| | Nerve Regeneration | 1 | 2010 | 50 | 0.360 |
Why?
| | Middle Aged | 30 | 2021 | 26719 | 0.350 |
Why?
| | Female | 47 | 2023 | 59466 | 0.350 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 529 | 0.350 |
Why?
| | Double-Blind Method | 7 | 2023 | 1660 | 0.350 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 38 | 0.340 |
Why?
| | Rats | 12 | 2021 | 4958 | 0.340 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 19 | 0.330 |
Why?
| | Meningioma | 2 | 2023 | 77 | 0.330 |
Why?
| | Immune System Phenomena | 1 | 2009 | 2 | 0.330 |
Why?
| | Virus Diseases | 1 | 2011 | 194 | 0.330 |
Why?
| | Cell Survival | 2 | 2019 | 1020 | 0.320 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 1982 | 0.320 |
Why?
| | Nervous System Diseases | 2 | 2020 | 253 | 0.310 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 91 | 0.300 |
Why?
| | Neurology | 2 | 2007 | 84 | 0.300 |
Why?
| | Ophthalmology | 2 | 2007 | 77 | 0.300 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 122 | 0.300 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 92 | 0.290 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1736 | 0.290 |
Why?
| | Antibodies | 3 | 2017 | 371 | 0.290 |
Why?
| | Mutation | 6 | 2019 | 3344 | 0.280 |
Why?
| | Proteomics | 2 | 2012 | 836 | 0.280 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 21 | 0.280 |
Why?
| | Immunization, Passive | 3 | 2020 | 73 | 0.270 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 41 | 0.270 |
Why?
| | Adolescent | 16 | 2023 | 17831 | 0.270 |
Why?
| | Protein Binding | 6 | 2019 | 1889 | 0.270 |
Why?
| | Corpus Callosum | 1 | 2006 | 56 | 0.270 |
Why?
| | Antibody Formation | 1 | 2007 | 266 | 0.260 |
Why?
| | Young Adult | 13 | 2023 | 10455 | 0.260 |
Why?
| | Atrophy | 2 | 2023 | 152 | 0.260 |
Why?
| | Herpes Zoster | 3 | 2015 | 331 | 0.250 |
Why?
| | Male | 33 | 2022 | 55555 | 0.250 |
Why?
| | Syndecan-1 | 4 | 2011 | 27 | 0.250 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 25 | 0.240 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 168 | 0.240 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 18 | 0.240 |
Why?
| | Acute Disease | 3 | 2018 | 910 | 0.240 |
Why?
| | Risk Assessment | 4 | 2021 | 2967 | 0.230 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 36 | 0.230 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1342 | 0.230 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 27 | 0.230 |
Why?
| | Prospective Studies | 8 | 2023 | 6217 | 0.230 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.230 |
Why?
| | Peptide Library | 4 | 2011 | 81 | 0.230 |
Why?
| | Proteolipids | 1 | 2023 | 28 | 0.220 |
Why?
| | Proteoglycans | 1 | 2004 | 107 | 0.220 |
Why?
| | Oligodendroglia | 2 | 2017 | 148 | 0.220 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 170 | 0.220 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 750 | 0.220 |
Why?
| | Epitope Mapping | 4 | 2017 | 51 | 0.220 |
Why?
| | Neuroprotection | 1 | 2023 | 30 | 0.210 |
Why?
| | Seroconversion | 1 | 2023 | 45 | 0.210 |
Why?
| | Immune System | 1 | 2004 | 172 | 0.210 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 219 | 0.210 |
Why?
| | Vision Disorders | 2 | 2021 | 130 | 0.210 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 128 | 0.210 |
Why?
| | Cells, Cultured | 7 | 2016 | 3881 | 0.210 |
Why?
| | Mice, Transgenic | 5 | 2018 | 1947 | 0.200 |
Why?
| | Aged | 16 | 2021 | 19061 | 0.200 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2785 | 0.200 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 430 | 0.200 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 493 | 0.200 |
Why?
| | Protein Isoforms | 4 | 2017 | 338 | 0.190 |
Why?
| | Autoantigens | 4 | 2020 | 396 | 0.190 |
Why?
| | Antibody Affinity | 2 | 2019 | 52 | 0.190 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 165 | 0.190 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 21 | 0.190 |
Why?
| | Internationality | 2 | 2019 | 143 | 0.180 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 25 | 0.180 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1037 | 0.180 |
Why?
| | Cell Proliferation | 3 | 2020 | 2186 | 0.180 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 35 | 0.180 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 34 | 0.180 |
Why?
| | Azathioprine | 1 | 2020 | 49 | 0.170 |
Why?
| | Interferon-gamma | 1 | 2023 | 719 | 0.170 |
Why?
| | Viral Vaccines | 1 | 2020 | 88 | 0.170 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 32 | 0.170 |
Why?
| | Myelin Proteins | 2 | 2017 | 42 | 0.170 |
Why?
| | Steroids | 1 | 2020 | 144 | 0.170 |
Why?
| | Cell Separation | 2 | 2015 | 291 | 0.170 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 12 | 0.160 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 284 | 0.160 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 380 | 0.160 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 56 | 0.160 |
Why?
| | Communicable Diseases | 1 | 2020 | 129 | 0.160 |
Why?
| | Peptides | 2 | 2019 | 848 | 0.160 |
Why?
| | Cell Lineage | 1 | 2020 | 309 | 0.160 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 8 | 0.160 |
Why?
| | Oxidoreductases | 1 | 2019 | 92 | 0.160 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 8 | 0.160 |
Why?
| | Retrospective Studies | 9 | 2023 | 12542 | 0.160 |
Why?
| | Treatment Outcome | 10 | 2021 | 9084 | 0.150 |
Why?
| | Animals, Newborn | 2 | 2018 | 778 | 0.150 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.150 |
Why?
| | Mice, Knockout | 9 | 2017 | 2565 | 0.150 |
Why?
| | Point Mutation | 1 | 2019 | 216 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 60 | 0.150 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 72 | 0.150 |
Why?
| | Cohort Studies | 5 | 2022 | 4894 | 0.150 |
Why?
| | Antibodies, Viral | 4 | 2023 | 520 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 687 | 0.150 |
Why?
| | Child | 11 | 2023 | 18404 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 439 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
| | Spatial Analysis | 1 | 2017 | 20 | 0.140 |
Why?
| | Skull Neoplasms | 1 | 2017 | 22 | 0.140 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.140 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 70 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4411 | 0.140 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 40 | 0.140 |
Why?
| | Orbital Diseases | 1 | 2017 | 25 | 0.140 |
Why?
| | Albumins | 1 | 2017 | 89 | 0.140 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 89 | 0.140 |
Why?
| | Microvessels | 1 | 2017 | 68 | 0.140 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6344 | 0.140 |
Why?
| | Interleukin-6 | 1 | 2020 | 676 | 0.140 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 325 | 0.140 |
Why?
| | Fibrinogen | 1 | 2017 | 154 | 0.130 |
Why?
| | HEK293 Cells | 4 | 2022 | 591 | 0.130 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 304 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 497 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3244 | 0.130 |
Why?
| | Ethics, Research | 1 | 2015 | 34 | 0.130 |
Why?
| | Treatment Failure | 1 | 2016 | 331 | 0.130 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 5 | 0.130 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 7 | 0.130 |
Why?
| | Models, Molecular | 2 | 2017 | 1369 | 0.130 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 201 | 0.120 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 396 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 338 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 330 | 0.120 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.120 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 63 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.120 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2019 | 591 | 0.120 |
Why?
| | Visual Pathways | 2 | 2007 | 44 | 0.120 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 796 | 0.120 |
Why?
| | Plasma Exchange | 1 | 2014 | 12 | 0.120 |
Why?
| | Alanine | 1 | 2015 | 104 | 0.120 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 79 | 0.120 |
Why?
| | Nerve Fibers | 1 | 2015 | 87 | 0.120 |
Why?
| | Glycine | 1 | 2015 | 152 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1518 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1842 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 923 | 0.110 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 241 | 0.110 |
Why?
| | Erythropoietin | 1 | 2014 | 72 | 0.110 |
Why?
| | Transcriptome | 2 | 2020 | 725 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2218 | 0.110 |
Why?
| | Proteome | 2 | 2015 | 339 | 0.110 |
Why?
| | Placenta Diseases | 1 | 2013 | 13 | 0.110 |
Why?
| | Biomedical Research | 1 | 2019 | 585 | 0.110 |
Why?
| | Fetal Death | 1 | 2013 | 50 | 0.110 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 1879 | 0.110 |
Why?
| | Phenotype | 3 | 2020 | 2796 | 0.110 |
Why?
| | Antibody Specificity | 2 | 2011 | 176 | 0.110 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 9 | 0.110 |
Why?
| | Computer Simulation | 1 | 2017 | 872 | 0.100 |
Why?
| | Syndrome | 2 | 2019 | 333 | 0.100 |
Why?
| | Quality of Life | 1 | 2023 | 2353 | 0.100 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 22 | 0.100 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 140 | 0.100 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 83 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1317 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2017 | 681 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 616 | 0.100 |
Why?
| | Exanthema | 1 | 2013 | 74 | 0.100 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 98 | 0.100 |
Why?
| | Antigens, CD20 | 2 | 2023 | 27 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 123 | 0.100 |
Why?
| | Area Postrema | 1 | 2011 | 1 | 0.100 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 5 | 0.100 |
Why?
| | Cranial Sinuses | 1 | 2011 | 12 | 0.100 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 13 | 0.100 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 27 | 0.100 |
Why?
| | Fundus Oculi | 1 | 2011 | 40 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2015 | 633 | 0.100 |
Why?
| | Cerebral Angiography | 2 | 2011 | 109 | 0.090 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 102 | 0.090 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 66 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3328 | 0.090 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 6 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 152 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2013 | 230 | 0.090 |
Why?
| | Databases, Factual | 1 | 2015 | 1124 | 0.090 |
Why?
| | Cell Line | 3 | 2011 | 2635 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1466 | 0.090 |
Why?
| | Research Design | 1 | 2015 | 928 | 0.090 |
Why?
| | Spinal Puncture | 1 | 2009 | 19 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6112 | 0.080 |
Why?
| | Brain Injuries | 1 | 2014 | 461 | 0.080 |
Why?
| | Genes | 1 | 2009 | 223 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2013 | 429 | 0.080 |
Why?
| | Risk Factors | 3 | 2015 | 8628 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2011 | 444 | 0.080 |
Why?
| | Blindness | 1 | 2008 | 37 | 0.080 |
Why?
| | Optic Disk | 1 | 2008 | 38 | 0.080 |
Why?
| | Clone Cells | 3 | 2017 | 247 | 0.080 |
Why?
| | Transfection | 3 | 2018 | 866 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 610 | 0.080 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 445 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 15 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 14 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 249 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 79 | 0.070 |
Why?
| | Molecular Biology | 2 | 2009 | 56 | 0.070 |
Why?
| | Visual Fields | 1 | 2007 | 77 | 0.070 |
Why?
| | Health | 1 | 2007 | 74 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 11 | 0.070 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 5 | 0.070 |
Why?
| | Bevacizumab | 1 | 2007 | 115 | 0.070 |
Why?
| | Measles virus | 1 | 2006 | 10 | 0.070 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 24 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 82 | 0.070 |
Why?
| | Vitreous Body | 1 | 2007 | 101 | 0.070 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.070 |
Why?
| | Binding, Competitive | 2 | 2019 | 193 | 0.070 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 43 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2710 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 9108 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 92 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 214 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1018 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 101 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 313 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 699 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1352 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 222 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 498 | 0.060 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.060 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 43 | 0.060 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 16 | 0.060 |
Why?
| | Risk | 1 | 2007 | 812 | 0.060 |
Why?
| | Patient Selection | 1 | 2008 | 641 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2084 | 0.060 |
Why?
| | Granzymes | 1 | 2024 | 40 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 42 | 0.060 |
Why?
| | Feasibility Studies | 1 | 2006 | 739 | 0.060 |
Why?
| | Neurons | 3 | 2017 | 1279 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 195 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 67 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 12 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 10 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2380 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 18 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1036 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 94 | 0.050 |
Why?
| | Complement Inactivating Agents | 1 | 2023 | 41 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 160 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 58 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 127 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 41 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 87 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 146 | 0.050 |
Why?
| | Eye | 1 | 2002 | 98 | 0.050 |
Why?
| | Binding Sites | 2 | 2017 | 1168 | 0.050 |
Why?
| | Glycoproteins | 1 | 2023 | 304 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 397 | 0.050 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 30 | 0.050 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 7 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 537 | 0.050 |
Why?
| | Pregnancy | 3 | 2013 | 5517 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2114 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 175 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 335 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2020 | 3003 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 112 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 84 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1620 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 695 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 150 | 0.040 |
Why?
| | Serum | 1 | 2019 | 57 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2021 | 271 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 160 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 811 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 49 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1211 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 255 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2009 | 323 | 0.040 |
Why?
| | Recovery of Function | 1 | 2021 | 574 | 0.040 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 14 | 0.040 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.040 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 15 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 143 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 68 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 197 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1226 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 58 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 133 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 129 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1578 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 99 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 157 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 3 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 497 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 442 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 797 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 322 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 276 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 352 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 382 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 345 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 42 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 487 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 38 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 323 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 213 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2279 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 21 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2894 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 35 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 9 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 18 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 62 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 382 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 182 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 615 | 0.030 |
Why?
| | Narcolepsy | 1 | 2013 | 19 | 0.030 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 19 | 0.030 |
Why?
| | Pyrans | 1 | 2012 | 3 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2387 | 0.030 |
Why?
| | Vaccination | 1 | 2020 | 1204 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 161 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2015 | 380 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 101 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 81 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 36 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 34 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2537 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 225 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 8 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 198 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 502 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1372 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 192 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 271 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 286 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 123 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 561 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 931 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 126 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1749 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 213 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 123 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1448 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 206 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 112 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 36 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 645 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 35 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 8 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 362 | 0.020 |
Why?
| | Water | 1 | 2012 | 396 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1629 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 142 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2249 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 135 | 0.020 |
Why?
| | B-Lymphocyte Subsets | 1 | 2009 | 68 | 0.020 |
Why?
| | Virion | 1 | 2009 | 73 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 320 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 206 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 273 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 442 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 785 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 399 | 0.020 |
Why?
| | Glioma | 1 | 2010 | 294 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 350 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2311 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 959 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1143 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1840 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 718 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4405 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1141 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7959 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 6 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 9 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 10 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1104 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 723 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 668 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 530 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2319 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1214 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1394 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 4509 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 4620 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|